You can read the article here and I have also put it in the Articles section for future access.
It’s good to hear that results so far seem to show this drug is beneficial for patients with Still’s Disease longterm; the initial response to the treatment in these patients is more than encouraging and now it seems this lasts. It is worth noting that 28% of the patients developed a serious infection but that risk is there with most treatment options and I can’t say whether this is any higher than average.
My Rheumatologist was itching for me to try Anakinra last year but unfortunately, when I did, I didn’t respond typically and a few months later was back on Enbrel. I hope it is working for others though and will continue to follow studies such as this one.